Evidence map›Paper›PMID 35310733›Full record

ArticleDEN open2022

Utility of autologous fecal microbiota transplantation and elucidation of microbiota in diversion colitis.

Kentaro Tominaga, Atsunori Tsuchiya, Takeshi Mizusawa, Asami Matsumoto, Ayaka Minemura, Kentaro Oka, Motomichi Takahashi, Tomoaki Yoshida, Yuichi Kojima, Kohei Ogawa and 17 more

Open access · goldAbstract read
In one paragraph

Article in DEN open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 2 institutions in 1 country.

Kentaro TominagaDivision of Gastroenterology and Hepatology Graduate School of Medical and Dental Sciences Niigata University Niigata Japan.ORCID https://orcid.org/0000-0001-6792-1005
Atsunori TsuchiyaDivision of Gastroenterology and Hepatology Graduate School of Medical and Dental Sciences Niigata University Niigata Japan.
Takeshi MizusawaDivision of Gastroenterology and Hepatology Graduate School of Medical and Dental Sciences Niigata University Niigata Japan.
Asami MatsumotoR&D Division Miyarisan Pharmaceutical Co. Ltd. Saitama Japan.
Ayaka MinemuraR&D Division Miyarisan Pharmaceutical Co. Ltd. Saitama Japan.
Kentaro OkaR&D Division Miyarisan Pharmaceutical Co. Ltd. Saitama Japan.
Motomichi TakahashiR&D Division Miyarisan Pharmaceutical Co. Ltd. Saitama Japan.ORCID https://orcid.org/0000-0003-4773-5904
Tomoaki YoshidaDivision of Gastroenterology and Hepatology Graduate School of Medical and Dental Sciences Niigata University Niigata Japan.
Yuichi KojimaDivision of Gastroenterology and Hepatology Graduate School of Medical and Dental Sciences Niigata University Niigata Japan.
Kohei OgawaDivision of Gastroenterology and Hepatology Graduate School of Medical and Dental Sciences Niigata University Niigata Japan.
Yuzo KawataDivision of Gastroenterology and Hepatology Graduate School of Medical and Dental Sciences Niigata University Niigata Japan.
Nao NakajimaDivision of Gastroenterology and Hepatology Graduate School of Medical and Dental Sciences Niigata University Niigata Japan.
Naruhiro KimuraDivision of Gastroenterology and Hepatology Graduate School of Medical and Dental Sciences Niigata University Niigata Japan.
Hiroyuki AbeDivision of Gastroenterology and Hepatology Graduate School of Medical and Dental Sciences Niigata University Niigata Japan.
Toru SetsuDivision of Gastroenterology and Hepatology Graduate School of Medical and Dental Sciences Niigata University Niigata Japan.
Kazuya TakahashiDivision of Gastroenterology and Hepatology Graduate School of Medical and Dental Sciences Niigata University Niigata Japan.
Hiroki SatoDivision of Gastroenterology and Hepatology Graduate School of Medical and Dental Sciences Niigata University Niigata Japan.
Satoshi IkarashiDivision of Gastroenterology and Hepatology Graduate School of Medical and Dental Sciences Niigata University Niigata Japan.ORCID https://orcid.org/0000-0001-7271-7762
Kazunao HayashiDivision of Gastroenterology and Hepatology Graduate School of Medical and Dental Sciences Niigata University Niigata Japan.
Ken-Ichi MizunoDivision of Gastroenterology and Hepatology Graduate School of Medical and Dental Sciences Niigata University Niigata Japan.
Junji YokoyamaDivision of Gastroenterology and Hepatology Graduate School of Medical and Dental Sciences Niigata University Niigata Japan.
Yosuke TajimaDivision of Digestive and General Surgery Graduate School of Medical and Dental Sciences Niigata University Niigata Japan.
Masato NakanoDivision of Digestive and General Surgery Graduate School of Medical and Dental Sciences Niigata University Niigata Japan.
Yoshifumi ShimadaDivision of Digestive and General Surgery Graduate School of Medical and Dental Sciences Niigata University Niigata Japan.
Hitoshi KameyamaDivision of Digestive and General Surgery Graduate School of Medical and Dental Sciences Niigata University Niigata Japan.
Toshifumi WakaiDivision of Digestive and General Surgery Graduate School of Medical and Dental Sciences Niigata University Niigata Japan.
Shuji TeraiDivision of Gastroenterology and Hepatology Graduate School of Medical and Dental Sciences Niigata University Niigata Japan.
Niigata University · JPTaiho Pharmaceutical (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Diversion colitis (DC) is an inflammatory disorder caused by interruption of the fecal stream and subsequent nutrient deficiency from luminal bacteria. The utility of fecal microbiota transplantation (FMT) for DC was recently investigated; however, the precise pathogenesis of this condition remains unclear. This study aimed to evaluate the utility of autologous FMT in DC and to determine the related changes in the intestinal microbiota. Methods: Autologous FMT was performed to reestablish the intestinal microbiota in five patients (average age, 64.6 ± 8.3 years) with DC. They underwent double-ended colostomy. We assessed the diverted colon by endoscopy and evaluated the microbiota before and after FMT using the 16S rRNA gene sequencing method. Results: All five patients had mild inflammation (ulcerative colitis endoscopic index of severity [UCEIS] 2-3) in the diverted colon based on the colonoscopic findings. Three patients presented with symptoms, such as tenesmus, mucoid stool, and bloody stool. With FMT treatment, all patients achieved endoscopic remission (UCEIS score of 0 or 1) and symptomatic improvement. We observed a significantly decreased α-diversity in DC patients compared to healthy controls. The frequency of aerobic bacteria, such as Conclusions: This study was the first to show that the microbiota in the diverted colon was significantly affected by autologous FMT. Since interruption of the fecal stream is central to the development of DC, FMT can be considered a promising treatment.

Indexed as

colostomydiversion colitisEnterobacteriaceaefecal microbiota transplantationintestinal microbiota

Identifiers

PMID35310733
PMCPMC8828251
OpenAlexW3209163907

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.